Effective Treatment for Severe Pneumonia in Geriatric Patients

Strategic Insights -

Researchers from the Department of Hematology conducted a study to explore the effectiveness of a new treatment regimen for geriatric patients with severe pneumonia and respiratory failure. The study involved 90 patients, divided into two groups: a control group that received conventional treatment, and an observation group that received a combination of bronchoalveolar lavage (BAL) and high-dose ambroxol hydrochloride (HD-AH). The results showed that the BAL + HD-AH treatment group had significantly better outcomes, including improved clinical efficacy, symptom relief, postoperative recovery, pulmonary function, and reduced risks of multiple organ dysfunction syndrome (MODS) and mortality.

Key Takeaways:

  • The BAL + HD-AH treatment regimen improved total effective rate, symptom relief, postoperative recovery, and pulmonary function in geriatric patients with severe pneumonia and respiratory failure.
  • The treatment reduced inflammatory markers, improved arterial blood gas parameters, and lowered the risks of MODS and mortality.
  • The treatment was found to be safe and effective, accelerating rehabilitation, reducing inflammation, and improving respiratory mechanics.
  • The study concluded that the BAL + HD-AH regimen is an effective treatment option for elderly patients with severe pneumonia and respiratory failure.
  • The Department of Hematology's research highlighted the importance of early treatment and interventions to prevent complications and improve outcomes in geriatric patients with severe pneumonia and respiratory failure.

Statistics:

  • 42 patients received the control treatment, while 48 patients received the BAL + HD-AH treatment.
  • The total effective rate was significantly higher in the BAL + HD-AH treatment group (85.4% vs. 48.8%).
  • The time to symptom relief was faster in the BAL + HD-AH treatment group (3.5 ± 1.1 days vs. 6.2 ± 1.3 days).
  • The postoperative recovery time was shorter in the BAL + HD-AH treatment group (4.8 ± 1.2 days vs. 7.3 ± 1.5 days).
  • The incidence of MODS was significantly lower in the BAL + HD-AH treatment group (4.2% vs. 14.3%).
  • The mortality rate was significantly lower in the BAL + HD-AH treatment group (2.1% vs. 10.1%).

Sources:

  • Effect of bronchoalveolar lavage combined with high-dose ambroxol hydrochloride on severe pneumonia with respiratory failure. American Journal of Translational Research, 2025;17(9):7170-7179.
  • NewsRx. Research from Department of Hematology Yields New Findings on Pneumonia (Effect of bronchoalveolar lavage combined with high-dose ambroxol hydrochloride on severe pneumonia with respiratory failure). Respiratory Therapeutics Week. November 3, 2025; p 5363.